Business
CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial
CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial.
About this update from Skylight Health Group Inc.
[{"type":"text","content":"\n Partnership Underway to Develop Extensive Protocols and Submissions for US Food & Drug Administration to Uncover Safety and Efficacy for Targeted Medical Cannabis Treatments in the US CB2 chosen to advance application with the US FDA for study on safety and efficacy of cannabis-based topical treatments by leading multistate operator, Vireo.Project marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management.  Company will develop full protocols and manage Investigational New Drug (IND) application on behalf of Vireo and will work with the FDA towards approvals.Vireo will also be licensing the Company’s Sail technology platform for full data collection to ensure structured, clean data availability when required. TORONTO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced it has partnered with Licensed Producer, Vireo Health International Inc. (“Vireo”) (CNSX: VREO, OTCQX: VREOF), to advance the proof of safety and efficacy for cannabinoid therapy as it relates to metered-dosing for patients with ailments in which cannabis-based medicine is believed to support.   CB2 will oversee the protocol development and Investigational New Drug (IND) Application directly with the US Food & Drug Administration (FDA).  The successful completion will position Vireo for industry leadership when it comes to cannabis-based topical medication used to treat pain.  Vireo will also license the Company’s Sail technology platform for full data collection and management.    “Vireo is a cannabis company that understands the importance of full-scale research to prove out the true safety and efficacy of their products as they come to market,” said Prad Sekar, CEO, CB2 Insights.  “As we have seen with the FDA over the past year, they are steadfast in ensuring that cannabis-based medicines follow the same protocols as other traditional pharmaceuticals.  We are proud to have been chosen to advance that process with Vireo as we move forward with the IND application.̶...